Fass Ronnie, Frazier Rosita
Professor of Medicine, Case Western Reserve University, Director, Division of Gastroenterology and Hepatology, Head, Esophageal and Swallowing Center, MetroHealth Medical Center, 2500 MetroHealth Drive, Cleveland, OH 44109, USA.
The Esophageal and Swallowing Center, Division of Gastroenterology and Hepatology, MetroHealth Medical Center and Case Western Reserve University, Cleveland, OH, USA.
Therap Adv Gastroenterol. 2017 Feb;10(2):243-251. doi: 10.1177/1756283X16681701. Epub 2017 Jan 5.
Dexlansoprazole modified-release (MR) is the R-enantiomer of lansoprazole and is currently the only proton-pump inhibitor (PPI) with a novel dual delayed release (DDR) formulation. Overall, dexlansoprazole MR demonstrates a similar safety and side-effect profile as lansoprazole. Dexlansoprazole MR has been shown to be highly efficacious in healing erosive esophagitis, maintaining healed esophageal mucosa in patients with erosive esophagitis and controlling symptoms of patients with nonerosive reflux disease (NERD). Recent studies have also demonstrated that dexlansoprazole MR is highly effective in improving nocturnal heartburn, gastroesophageal reflux disease (GERD) related sleep disturbances and bothersome regurgitation. Dexlansoprazole MR is well tolerated and can be taken without regard to food.
右兰索拉唑缓释片（MR）是兰索拉唑的R-对映体，是目前唯一采用新型双延迟释放（DDR）制剂的质子泵抑制剂（PPI）。总体而言，右兰索拉唑缓释片的安全性和副作用与兰索拉唑相似。已证明右兰索拉唑缓释片在治疗糜烂性食管炎、维持糜烂性食管炎患者愈合的食管黏膜以及控制非糜烂性反流病（NERD）患者症状方面具有高效性。最近的研究还表明，右兰索拉唑缓释片在改善夜间烧心、胃食管反流病（GERD）相关睡眠障碍和令人烦恼的反流方面非常有效。右兰索拉唑缓释片耐受性良好，无需考虑进食情况即可服用。
